PAVmed

PAVM · NASDAQ

$2.23−$0.02 (−0.89%)TodayMarket closed · Oct 20, 7:21 PM ET

Prev close $2.25

PAVM analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $37.23 (+1569.5% upside)

Low: $16.16
Now: $2.23
High: $59.85

Upgrades and downgrades

The latest rating actions, newest first

PAVM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Aug 27, 2026	Maintains	Buy	$56.00 → $57.00	28%
Ascendiant Capital	Jun 8, 2026	Maintains	Buy	$65.00 → $56.00	28%
Ascendiant Capital	Apr 9, 2026	Maintains	Buy	$510.00 → $65.00	28%
Ascendiant Capital	Dec 10, 2025	Maintains	Buy	$20.00 → $17.00	28%

The case for and against

Updated Mar 27, 2026

Bull case

PAVmed Inc. has demonstrated a positive growth trajectory in its EsoGuard testing, with a sequential increase in the number of tests processed from 2,756 in Q2 to 2,841 in Q3, highlighting increasing market demand for its diagnostic services. The company's valuation is seen as attractive, as it appropriately reflects a balance of inherent risks while indicating substantial upside potential, further supported by an upward revision in the 12-month price target based on net present value analysis. Additionally, the anticipated growth of its newly commercialized products is expected to significantly contribute to revenues in 2025 and 2026, enhancing the overall positive financial outlook for PAVmed.

Bear case

PAVmed Inc. reported a pro forma net loss of $0.8 million for the latest quarter, indicating a continued struggle with profitability as it fell short of both its own and consensus earnings estimates. The decline in the number of EsoGuard tests processed, which decreased to 2,756 from 3,034 in the previous quarter, highlights potential challenges in demand for its diagnostic services. Additionally, the company faces numerous risks including liquidity concerns, regulatory hurdles, and market competition, which collectively contribute to a negative outlook on its financial performance and future growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.